Literature DB >> 18941125

The outcome of prostate cancer screening in a normal Japanese population with PSA of 2-4 ng/ml and the free/total PSA under 12%.

Shigeto Ishidoya1, Akihiro Ito, Kazuhiko Orikasa, Sadafumi Kawamura, Tatsuo Tochigi, Masaaki Kuwahara, Takuya Yamanobe, Yoshihiko Tomita, Naoya Masumori, Taiji Tsukamoto, Daisuke Shibuya, Yoichi Arai.   

Abstract

OBJECTIVE: No previous study has reported the numbers of prostate cancer (PC) patients existing among a normal Japanese population with prostate-specific antigen (PSA) < 4 ng/ml. The aim of this study was to elucidate the performance of %free PSA as a screening tool for a normal Japanese population with PSA of 2-4 ng/ml and to examine the characteristics of cancer detected using this criterion.
METHODS: We conducted a prospective, multi-center study to evaluate the performance of %free PSA among a normal Japanese population. We decided on a %free PSA cutoff value of 12% according to the preliminary results. A total of 5548 consecutive screening volunteers aged 50-79 years were enrolled in the project. Men with total PSA > 4 ng/ml, or men with total PSA of 2-4 ng/ml and %free PSA of < or =12% were indicated to undergo 12 core biopsies.
RESULTS: There were 826 (14.9%) men with PSA of 2-4 ng/ml. Among them, those with %free PSA of < or =12% numbered 100 (12.1%). Forty-nine out of 100 men (49%) received biopsy, and 16 PC patients were detected. Among 10 patients undergoing radical prostatectomy, seven were associated with extra-prostatic extension (pT3) or high-grade cancer (Gleason score > or = 8).
CONCLUSIONS: We confirmed the ability of %free PSA and demonstrated that there are considerable numbers of PC patients among the normal Japanese population with PSA of 2-4 ng/ml. We ascertained that cancers detected in this study had a variety of tumor characteristics, including those of an aggressive nature.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18941125     DOI: 10.1093/jjco/hyn107

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  7 in total

Review 1.  Prostate cancer: an emerging threat to the health of aging men in Asia.

Authors:  Ling Zhang; Bao-Xue Yang; Hai-Tao Zhang; Jin-Guo Wang; Hong-Liang Wang; Xue-Jian Zhao
Journal:  Asian J Androl       Date:  2011-05-09       Impact factor: 3.285

2.  The value of prostate-specific antigen in Asia.

Authors:  Chaidir Arif Mochtar; R Siddhi Andika
Journal:  Ther Adv Urol       Date:  2010-04

3.  Longitudinal evaluation of apparent diffusion coefficient values as a predictor of Prostate Cancer Research International Active Surveillance reclassification.

Authors:  Eri Ota; Naoko Mori; Shinichi Yamashita; Shunji Mugikura; Akihiro Ito; Kei Takase
Journal:  Abdom Radiol (NY)       Date:  2021-12-09

4.  Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1-10.0 ng/ml at population screening.

Authors:  Yasuhide Kitagawa; Satoru Ueno; Kouji Izumi; Yoshifumi Kadono; Hiroyuki Konaka; Atsushi Mizokami; Mikio Namiki
Journal:  J Cancer Res Clin Oncol       Date:  2013-10-29       Impact factor: 4.553

5.  Prostate cancer detection upon transrectal ultrasound-guided biopsy in relation to digital rectal examination and prostate-specific antigen level: what to expect in the Chinese population?

Authors:  Jeremy Yc Teoh; Steffi Kk Yuen; James Hl Tsu; Charles Kw Wong; Brian Sh Ho; Ada Tl Ng; Wai-Kit Ma; Kwan-Lun Ho; Ming-Kwong Yiu
Journal:  Asian J Androl       Date:  2015 Sep-Oct       Impact factor: 3.285

Review 6.  Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia.

Authors:  Yasuhide Kitagawa; Mikio Namiki
Journal:  Asian J Androl       Date:  2015 May-Jun       Impact factor: 3.285

7.  Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer.

Authors:  Choung Soo Kim; Young Deuk Choi; Sang Eun Lee; Hyun Moo Lee; Takeshi Ueda; Junji Yonese; Takashi Fukagai; Edmund Chiong; Weber Lau; Sarang Abhyankar; Ad Theeuwes; Bertrand Tombal; Tomasz M Beer; Go Kimura
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.